Primary Immune Deficiency (PID)

The HILO Study: High Volumes and Flow Rates of Subcutaneous IgPro20 Pump-assisted Infusions in Patients With Primary Immunodeficiency

View Poster

Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid

Safety Profile of High IgPro20 Infusion Parameters in Patients With Primary Immunodeficiency (PID): Results From the Forced Upward Titration HILO Study

View Poster

Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid

Feasibility of Subcutaneous IgPro20 Administration Via Manual Push at High Flow Rates in Patients With Primary Immunodeficiency: Findings of the HILO Study

View Poster

Please see full prescribing information for Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid

Immunoglobulin Replacement Therapy in Patients with Immunodeficiencies - Impact of Administration Method on Patient-Reported Outcomes

View Poster

Please see full prescribing information for Hizentra^®, Immune Globulin Subcutaneous (Human), 20% Liquid
Please see full prescribing information for Privigen^®, Immune Globulin Subcutaneous (Human), 10% Liquid

High treatment satisfaction with Hizentra, a 20% subcutaneous immunoglobulin (SCIG): Real-world survey data

View Poster

Please see full prescribing information for Hizentra^®, Immune Globulin Subcutaneous (Human), 20% Liquid
Please see full prescribing information for Privigen^®, Immune Globulin Subcutaneous (Human), 10% Liquid

Real-world experience of a cohort of previously untreated PI patients on SCIG

View Poster

Please see full prescribing information for Hizentra^®, Immune Globulin Subcutaneous (Human), 20% Liquid
Please see full prescribing information for Privigen^®, Immune Globulin Subcutaneous (Human), 10% Liquid

Isoagglutinin Reduction in IVIg by Specific Immunoaffinity Chromatography Reduces Spontaneous Reporting Rates of Hemolytic Reactions

View Poster

Please see full prescribing information for Privigen^®, Immune Globulin Subcutaneous (Human), 10% Liquid

Efficacy and Safety of a new 20% Immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with Primary Immunodeficiency

Efficacy and safety of Hizentra in patients with Primary Immunodeficiency after a dose-equivalent switch from IV or SC replacement therapy

Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with Primary Immunodeficiency Diseases

Long-Term efficacy, safety and tolerability of Hizentra for treatment of Primary Immunodeficiency Disease

Safety and Efficacy of Privigen, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in patients with Primary Immunodeficiencies

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purapura